Cervical Cancer - Epidemiology Forecast - 2034

Key Highlights

• Cervical cancer is most often diagnosed between the ages of 35 and 44. The average age of diagnosis in the US is 50. Over 20% of cervical cancers are diagnosed after age 65. It is rare for people younger than 20 to develop cervical cancer.
• Persistent infection with high-risk HPV strains, particularly HPV-16 and HPV-18, is the primary risk factor for developing cervical cancer.
• In 2022, the total incident cases of cervical cancer were nearly 42,500 in the 7MM, which is expected to decrease by 2034. The US, in 2022, accounted for the highest cases.
• Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases. In the United States, incidence rates showed a decline from the mid-1970s to the mid-2000s, attributed in part to increased screening efforts.

The "Cervical Cancer-Epidemiology Forecast-2034” report delivers an in-depth understanding of cervical cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Cervical Cancer Disease Understanding and Treatment Algorithm

Cervical Cancer Overview

Cervical cancer starts in the cells of the cervix. The cervix is the lower, narrow end of the uterus (womb); the cervix connects the uterus to the vagina (birth canal). Cervical cancer usually develops slowly over time. At first, the changes in a cell are abnormal, not cancerous, and are sometimes called “atypical cells.” Researchers believe that some of these abnormal changes are the first step in a series of slow changes that can lead to cancer. Before cancer appears in the cervix, the cells of the cervix go through dysplasia, and abnormal cells begin to appear in the cervical tissue. Over time, if not destroyed or removed, the abnormal cells may become cancer cells and start to grow and spread more deeply into the cervix and to surrounding areas.

Cervical Cancer Diagnosis

Diagnosis of cervical cancer typically involves several steps. Initially, a thorough medical history is taken, encompassing any pertinent symptoms and risk factors. This is followed by a physical examination, including a pelvic exam, to detect any abnormalities in the cervix. A Pap smear, also known as a Pap test, is then conducted to screen for abnormal cervical cells. This involves collecting cells from the cervix and examining them under a microscope. Additionally, an HPV test may be performed concurrently to check for the presence of the human papillomavirus (HPV), a common cause of cervical cancer. Depending on the results of these tests, further diagnostic procedures such as colposcopy, biopsy, or imaging studies may be necessary to confirm the presence of cervical cancer and determine its extent.

Cervical Cancer Treatment

Treatment for cervical cancer varies depending on factors like the cancer's stage, the patient's health, and their preferences. Typically, options include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination. Surgical interventions may entail removing cancerous tissue or performing procedures like hysterectomy for advanced cases. Immunotherapy is another option, leveraging the body's immune system to fight cancer cells.

Cervical Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Cervical Cancer, Total Cervical Cancer Cases by histology, Stage-specific Cases of Cervical Cancer, and Age-specific Cases of Cervical Cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total incident cases of cervical cancer in the 7MM comprised 42,500 in 2022 and are projected to decrease during the forecast period.
• The US contributed to the largest incident population of cervical cancer, accounting for nearly 33% in the 7MM in 2022.
• Among the total cervical cancer cases by histology, the cases of squamous carcinoma comprised nearly 9,000 cases in 2022 in the US.
• Among the stage-specific cases of cervical cancer, Stage IB comprised the highest number of cases, followed by IVB in the US in 2022.
• Among EU4 and the UK, Germany accounted for the highest number of cervical cancer cases, followed by the UK, whereas Spain accounted for the lowest cases in 2022.

KOL- Views

To keep up with current epidemiology trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, PhD, and others. Their opinion helps to understand and validate epidemiology patterns of cervical cancer.

The analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Cervical Dysplasia, Department of Gynecological Oncology, Division of Obstetrics and Gynecology, etc., were contacted. Their opinion helps understand and validate cervical cancer epidemiology trends.

Scope of the Report

• The report covers a descriptive overview of cervical cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into cervical cancer epidemiology.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Cervical Cancer Report Insights

Cervical Cancer Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

Cervical Cancer Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Cervical Cancer Epidemiology Segmentation

Cervical Cancer Report Assessment

• Current Diagnostic Practices
• Unmet Needs

FAQs

• What are the disease risks, burdens, and unmet needs of cervical cancer? What will be the growth opportunities across the 7MM concerning the patient population with cervical cancer?
• What is the historical and forecasted cervical cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• What is the diagnosis rate of cervical cancer?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the incident cases of cervical cancer in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.